D.E. Shaw & Co
KRYS icon

D.E. Shaw & Co’s Krystal Biotech KRYS Stock Holding History

D.E. Shaw & Co’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-996
Closed -$298K – 5060
2026
Q1 		$257K Sell
996
-1,112
-53% -$296K ﹤0.01% 4119
2025
Q4 		$520K Sell
2,108
-4,706
-69% -$990K ﹤0.01% 3913
2025
Q3 		$1.2M Sell
6,814
-4,913
-42% -$735K ﹤0.01% 3346
2025
Q2 		$1.61M Sell
11,727
-38,165
-76% -$5.61M ﹤0.01% 2903
2025
Q1 		$9M Buy
49,892
+42,465
+572% +$7.14M 0.01% 1477
2024
Q4 		$1.16M Sell
7,427
-1,919
-21% -$340K ﹤0.01% 3117
2024
Q3 		$1.7M Sell
9,346
-1,700
-15% -$328K ﹤0.01% 2833
2024
Q2 		$2.03M Sell
11,046
-70,981
-87% -$11.9M ﹤0.01% 2646
2024
Q1 		$14.6M Buy
82,027
+14,886
+22% +$2.07M 0.01% 1120
2023
Q4 		$8.33M Buy
67,141
+11,384
+20% +$1.26M 0.01% 1500
2023
Q3 		$6.47M Buy
55,757
+45,962
+469% +$5.61M 0.01% 1600
2023
Q2 		$1.15M Buy
9,795
+4,200
+75% +$429K ﹤0.01% 2996
2023
Q1 		$448K Sell
5,595
-805
-13% -$63.2K ﹤0.01% 3601
2022
Q4 		$507K Sell
6,400
-1,700
-21% -$126K ﹤0.01% 3841
2022
Q3 		$565K Hold
8,100
– – ﹤0.01% 3969
2022
Q2 		$532K Buy
8,100
+4,291
+113% +$267K ﹤0.01% 4053
2022
Q1 		$253K Buy
+3,809
New +$238K ﹤0.01% 4740
2021
Q4 		– Sell
-13,571
Closed -$709K – 5557
2021
Q3 		$709K Buy
13,571
+6,331
+87% +$375K ﹤0.01% 3859
2021
Q2 		$492K Buy
+7,240
New +$505K ﹤0.01% 4042

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

D.E. Shaw & Co's KRYS Position: Q2 2026 in Review

D.E. Shaw & Co sold out of Krystal Biotech (KRYS) in Q2 2026, closing a stake of 996 shares — an estimated $298K sold.

D.E. Shaw & Co first reported a position in KRYS in Q2 2021 and held it in 19 quarters. The position peaked at $14.6M in Q1 2024. 424 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • D.E. Shaw & Co reported no remaining Krystal Biotech position as of Q2 2026 after selling out during the quarter.
  • D.E. Shaw & Co sold 996 Krystal Biotech shares in Q2 2026, an estimated $298K.
  • D.E. Shaw & Co first reported a position in Krystal Biotech in Q2 2021 and held it in 19 quarters.
  • D.E. Shaw & Co's Krystal Biotech position peaked at $14.6M in Q1 2024.
  • 424 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.